Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China
Dinutuximab beta shows favorable efficacy for pediatric patients with high-risk NB. Patients treated with prior ASCT or combined with chemotherapy showed trends toward improved response rates and survival outcomes, although optimal treatment regimens required further investigation. AEs are generally manageable, and the use of standardized pain assessment combined with multimodal analgesia has enabled a substantial reduction in morphine exposure.
Authors
- Xisi Wang
- Chunying Cui (ORCID: https://orcid.org/0000-0001-7000-9412)
- Hongjun Fan (ORCID: https://orcid.org/0000-0002-1034-3221)
- Chao Duan (ORCID: https://orcid.org/0000-0003-4423-2156)
- Yue Wu (ORCID: https://orcid.org/0000-0002-9073-5988)
- Peiyi Yang (ORCID: https://orcid.org/0000-0002-0824-163X)
- Jing Qin
- M L Jin
- Wen Zhao
- Yan Su
- Cheng Huang
Institutions
- Capital Medical University (CN)
- Ministry of Education (KR)
- Beijing Children’s Hospital (CN)
- Ministry of Education and Child Care (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3389/fonc.2026.1765578
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China